Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brown-Forman Corporation Class B (BF.B) vs Medpace Holdings Inc (MEDP) Price & Performance

Brown-Forman Corporation Class BTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Brown-Forman Corporation Class B vs Medpace Holdings Inc — how do they compare? Brown-Forman Corporation Class B trades at $29.9, while Medpace Holdings Inc trades at $607 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Brown-Forman Corporation Class B nearer its low. Which is the better fit depends on your goals.

BF.BMEDP
Sector
Consumer StaplesTechnology
52-Week High
$31.26$620.59
52-Week Low
$22.80$393.42
Market Cap
$16.90B
Enterprise Value
$16.52B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Brown-Forman Corporation Class B

Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.

Read more on BF.B

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP